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Abstract
Background: Image-guided elastoplasty is an innovative method for percutaneous vertebral augmentation with a
silicone elastomeric material. Our aim was to evaluate its technical success, safety and efficacy as well as the rate of
secondary fractures.
Methods: Nineteen patients (13 women and 6 men, age 72 ± 10 years, mean ± standard deviation) underwent
elastoplasty between 2010 and 2016. A total of 33 vertebrae were treated. A total of 2–6 mL of silicone-based
elastomeric polymer material (VK100) was used. Visual analogue scale (VAS) and Oswestry disability index (ODI)
pain scores were used.
Results: In all cases, it was possible to complete the procedure (technical success 100%). No major complications
occurred. In 6/19 (31.5%) patients, asymptomatic leakage of the material was observed during the procedure. Full
pain recovery was obtained in 18/19 (94%) patients. One patient with a painful angioma did not experience any
change in symptoms. VAS and ODI were significantly reduced after the procedure, from 7.9 ± 1.1 to 0.7 ± 1.4 and
from 79.6 ± 12% to 9.9 ± 14% respectively (p < 0.001 for both comparisons). After vertebroplasty, 14 of 15 patients
(93%) removed the brace and 16/19 (84%) completely stopped using any drugs for pain relief (p < 0.001 for both
pre-procedure versus post-procedure comparisons). At a mean follow-up time of 26.5 ± 28.1 months (median 8.7 months,
range 6–69 months), no secondary fracture occurred.
Conclusion: Taking into consideration the relatively small sample size, image-guided elastoplasty seems to be a
safe procedure providing effective pain control over time.
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Key points
 Elastoplasty is an innovative method for vertebral
augmentation with a silicone elastomeric material.
 In a series of 19 patients, elastoplasty was a safe and
effective procedure.
 No symptomatic leakage of elastomeric material or
cases of pulmonary embolism were observed.
Background
Percutaneous vertebral augmentation is increasingly used
to achieve vertebral stabilisation and pain relief from symp-
tomatic vertebral lesions. With this technique, the stiffness
of the vertebral body is rapidly restored, reporting signifi-
cant pain relief and improvement in quality of life [1–4].
The most widely used method for vertebral augmentation
is vertebroplasty, which involves injection of surgical bone
cement. To this aim, polymethylmethacrylate (PMMA)
[5] presents a good characteristic in terms of viscosity,
polymerisation time and mechanical resistance. How-
ever, PMMA does have some shortcomings and is used
primarily because biomaterials available for vertebroplasty
were, until recently, limited to PMMA. Among the most
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feared complications of vertebroplasty is the possible leak-
age of material, which may damage surrounding tissue
and cause nerve compression with pain, spinal cord com-
pression, and even pulmonary embolism [1, 4]. Moreover,
as PMMA could be an irritant for soft tissue and is harder
and stiffer than natural bone, researchers have postulated
that the use of this material might increase the risk of adja-
cent vertebral fractures [6].
Therefore, the use of a silicone elastomeric material
(VK100) has been proposed to achieve vertebral stabil-
isation with a pliable material that has a modulus closer
to that of bone, thus theoretically reducing the risk of
adjacent fractures [7]. However, VK100 being less viscous
than PMMA, concerns exist due to a theoretical increased
risk of leakage. There are only a few reports regarding the
application of VK100 to perform vertebral stabilisation,
so-called ‘elastoplasty’, with different results. Urlings and
van der Linden reported 60% of pulmonary embolism in a
series of 12 patients, concluding that silicone material
should not be used for the treatment of vertebral fractures
[8]. In a different study comparing VK100 and PMMA
for vertebral stabilisation after balloon kyphoplasty in a
group of 30 patients, no significant difference was found
in material embolisation rates [7].
Thus, the primary aim of our work was to investigate
the technical feasibility and safety of VK100 elastoplasty.
The secondary aim was to assess pain management and the
rate of secondary fractures following VK100 elastoplasty.
Methods
Patient population
Institutional review board approval was obtained and patient
informed consent was waived for this retrospective study.
From 2003 to 2016, 4580 patients with back pain and differ-
ent kinds of vertebral lesions were presented to the same
interventional radiologist with more than 13 years of
experience; they were treated by percutaneous vertebral
augmentation at different institutions. Out of those patients,
19 (0.4%, 13 women and 6 men, age 72 ± 10 years, mean ±
standard deviation) underwent elastoplasty in a single insti-
tution. The indication for the treatment was the same as for
standard vertebral augmentation, which has been previously
reported [9–11].
Patients with no more than two vertebral fractures
were selected for elastoplasty and prepared for treatment
at one of the institutions where the material was available.
Fourteen patients had osteoporotic fractures, two patients
had traumatic fractures, one patient had a painful myeloma
localisation and one patient had a painful vertebral non-ag-
gressive angioma. Fifteen patients used a brace and all
were using drugs for pain relief. A total of 33 vertebrae
were treated (range T6–L5). Data of all treated patients
were prospectively collected in a dedicated database and
retrospectively extracted and analysed.
Technique
Elastoplasty was always performed using a sterile technique
in conjunction with prophylactic intravenous antibiotics (2 g
of Ceftriaxone) in a dedicated angiosuite equipped with
flat-panel digital fluoroscopy (Allura Xper CT; Philips, the
Netherlands). The procedure was always performed with
the anaesthesiologist in the room. Based on the patient’s
condition, it was decided whether to perform the procedure
under sedation (Midazolam, 2–5 mg) or general anaesthesia.
Vital signs (heart rate, pulse oximetry and blood pressure)
were monitored throughout the whole procedure. Under
fluoroscopic guidance, a 22-gauge Quincke needle was
placed over the pedicle periosteum and local anaesthesia
with ≤ 2 mL of 2% lidocaine hydrochloride was adminis-
tered. Bevelled access cannulas (13 G, Optimed, Ettlingen,
Germany) were inserted using the oblique projection and
subsequently advanced in the anteroposterior projection.
Once the desired position of the needles was achieved and
confirmed, 2–6 mL of silicone-based elastomeric polymer
material (VK100, BŌNWRx Ltd., Lansing, MI, USA) were
gently manually injected under continuous fluoroscopic
monitoring.
VK100 is composed of two paste components mixed
during application. Component A is composed of dimethyl
methylvinyl siloxanes (86%), barium sulfate powder (14%)
and a platinum catalyst (15 ppm as metal). Component B is
composed of dimethyl methylvinyl siloxanes (78%), barium
sulphate powder (15%) and a methylhydrogensiloxane
cross-linker (7%).
VK100 injection was stopped when satisfactory interver-
tebral material distribution was observed. When leakage
outside the vertebral body was detected, the procedure was
immediately interrupted and symptoms or modifications of
the vital signs were checked. After some minutes, injection
was cautiously restarted. If leakage was still present, the
injecting needle was slightly moved or rotated and injection
restarted. When VK100 injection was complete, the cannu-
las were withdrawn. Patients were discharged after 4–6 h of
observation. A case is shown in Figs. 1 and 2.
Endpoints and data analysis
Primary endpoints of the study were the technical success
and safety of the procedure. Technical success was defined
according to previously reported criteria for interventional
procedures [12] as the ability of completing the treatment
as preoperatively planned (i.e. achieving the desired filling
of the vertebral body). Complications were recorded
and classified according to the guidelines of the Society
of Interventional Radiology [12]. Moreover, evidence of
leakage during the procedure and presence of pulmon-
ary emboli detected at post-procedural chest x-ray were
recorded.
Secondary endpoints were the technical efficacy in
achieving pain relief and the rate of secondary fractures
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Fig. 1 A 72-year old male/female patient with lumbar vertebral fracture treated with image-guided elastoplasty. MRI before treatment: sagittal
T1-weighted (a), proton density-weighted (b), and T2-weighted (c) images. A lumbar vertebral fracture in L4 is clearly visualised as decreased
signal of the fractured vertebral body in (a) (arrow, a) and increased signal in fractured vertebral body in (b) and (c) (arrow)
Fig. 2 Same case as shown in Fig. 1. Elastoplasty procedure: injection of VK100 in the fractured body (L4) using the transpedicular approach
under fluoroscopic guidance. Preprocedural control x-rays; anteroposterior (a) and sagittal (b) view; fluoroscopy during transpedicular needle
insertion (arrow) showing correct placement of the needle into the vertebral body (c, d); postprocedural control x-rays showing the good filling
of L4 body (arrow, e, f)
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during follow-up (Fig. 3). Visual analogue scale (VAS)
was used to assess perceived pain before and after the
procedure [13] while quality of life was assessed using the
Oswestry Disability Index (ODI) [14] before and after the
procedure. Procedure was regarded as effective if a reduc-
tion of > 2 points in the VAS scale and of > 15 percentage
points in the ODI was obtained after the procedure.
All patients underwent a thoracic and lumbosacral spine
x-ray examination and a clinical visit one month after the
procedure. The number of patients who stopped to use a
brace and number of patients who stopped using any
medication for pain management were recorded. After
the examination and discharge, patients were asked to
immediately contact the interventional radiologist who
performed the procedure if they experience any increase or
restart of the back pain. In such cases, magnetic resonance
imaging (MRI) or computed tomography (CT) of the spine
were performed to asses for the presence of secondary
fractures. Where no pain was reported by the patients,
clinically relevant secondary fractures were excluded.
Statistical analysis
VAS and ODI scores before and after the procedure were
compared using the Mann-Whitney U test. The number
of patients who needed a brace and pain medications
before and after the treatment was compared using
Fisher’s exact test. Analysis was performed using GraphPad
Prism 5 software (Graph-Pad, La Jolla, CA, USA). A p value
< 0.05 was considered significant.
Results
In all cases it was possible to complete the procedure
and to reach a satisfactory filling of the vertebral body
(technical success 100%). No major complications occurred.
In 6/19 patients (31.5%), a minimal leakage of the material
was seen during the procedure. No change in the vital signs
or symptoms were recorded in these cases. After a few
minutes it was always possible to restart the procedure
and conclude it as planned. None of these patients had
modifications of the saturation parameters or symptoms
after the procedure.
The procedure was effective in achieving an improvement
in clinical symptoms in 18/19 patients (technical efficacy
94%). One patient with painful angioma did not experience
any change in symptoms. VAS and ODI scores were signifi-
cantly reduced after the procedure, from 7.9 ± 1.1 to 0.7 ±
1.4 (p < 0.001) and from 79.6 ± 12% to 9.9 ± 14% (p < 0.001),
respectively. Of 15 patients, 14 (93%) no longer required a
brace after the procedure (p < 0.001) and 16/19 (84%)
completely stopped using any drugs for pain relief after
treatment (p < 0.001).
At a mean follow-up time of 26.5 ± 28.1 months, no
patients developed new symptoms or demonstrated a
secondary fracture.
Discussion
Vertebral augmentation has been reported to be highly
effective in the relief of pain relief arising from vertebral
lesions; it is nowadays becoming increasingly widespread
in clinical practice. However, as already mentioned, one of
the major controversies regarding the clinical application
of vertebroplasty is the possible occurrence of secondary
vertebral fractures due to an increased stiffness of the
treated vertebral body [15]. In this scenario, the applica-
tion of a more pliable material than PMMA [7] to achieve
the vertebral stabilisation would be highly beneficial,
theoretically lowering the number of secondary fractures.
The results of the present study play in favour of the
effectiveness of elastoplasty with VK100 is in treating
painful vertebral lesions, with a low rate of minor antici-
pated complications and no major complications. Moreover,
no secondary fractures were found in our small series during
follow-up. In our series, the vertebral augmentation
procedure with VK100 was always feasible (technical
success 100%). According to the subjective experience of
the interventional radiologist, it was not more technically
difficult than standard vertebroplasty with PMMA.
Practitioners have suggested that VK100 may cause
an increased rate of leakage due to viscosity. However,
viscosity is a moving target. During the curing of PMMA
or the cross-linking of VK100, the viscosity is changing.
Fig. 3 Same case as shown in Figs. 1 and 2. Lumbosacral spine x-ray
examination performed one month after the elastoplasty procedure
demonstrating the good filling of L4 vertebral body (arrows). No
evidence of new vertebral fractures is seen
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Viscosity test data demonstrate that VK100 is equivalent to
PMMA as used in vertebral augmentation. At an ambient
temperature of 68–69 °F, it was shown that the average
viscosity of VK100 at the time of injection into the
vertebral body is 167,900 centipoise (cP) and the aver-
age viscosity of PMMA cements commonly used for
vertebroplasty is 136,300 cP [16]. Further, VK100 is
temperature-sensitive: as the temperature rises, the ma-
terial cross-links at a much faster rate. At normal body
temperature, it cross-links four times faster than at
room temperature; once in the body, VK100 solidifies
quickly and becomes too viscous to migrate. Moreover,
unlike PMMA which breaks into small pieces that can
travel in the body, VK100 strongly adheres to itself and
bone, and when it is injected into the vertebrae it creates a
single piece of silicone which sticks to the vertebral body.
The experience of the operator may play a relevant role
in reducing the complication rate. Appropriate training
should be used to achieve optimal results. In our series, all
the procedures were performed by the same operator with
more than 13 years of experience in vertebral augmenta-
tion procedures and no major complications occurred.
Minor leakage of VK100 outside the vertebral body was
seen in about 30% of cases during the procedure. Material
leakage has been reported to occur in vertebroplasty in a
highly variable rate. In a systematic review of 15 studies,
leakage of cement outside the vertebral body was reported
in a range of 3.3–75.6% [17]. Rate of leakage and pulmon-
ary embolism have been reported to be associated with
the viscosity of the material used [18]. Thus, from our and
previous experiences, elastoplasty seems to be similar to
PMMA with respect to leakage.
One of the most critical complications related to extraver-
tebral leakage of injected material is pulmonary embolism.
This occurrence has been reported in a variable range for
PMMA procedures [19–22]. Kim et al. [19] carried out
a prospective study aimed at detecting incidence and
understanding risk factor for pulmonary embolism in a
group of 78 patients treated with cement vertebroplasty;
they reported a rate of pulmonary embolism of about
23%. Urlings et al. [8] reported an extremely elevated rate
of 60% of pulmonary embolism with the use of VK100,
with one case of severe dyspnoea, and their results are
totally different from our experience. One hypothesis to
explain such a difference could be the different experience
in performing vertebral augmentation in the two series,
further underlying the crucial role of operator experience
in vertebral interventional procedures. In our series, to
avoid unnecessary radiation exposure, pulmonary CT
could have been performed only in patients with respiratory
symptoms such as dyspnoea. However, no patient presented
respiratory symptoms after the procedure or at follow-up.
Regarding the efficacy in pain relief, in a systematic
review on patients with osteoporotic vertebral compression
fractures, mean pain scores, measured using a 0 to 10 VAS
score, improved significantly from 7.8 to 3.1 (a 60.3%
reduction) immediately after percutaneous vertebroplasty
[23]. In our series, we achieved improvement in clinical
symptoms in 94% of the cases, with a significant improve-
ment in both VAS and ODI scores. Pain relief was noted
almost immediately after the procedure, as happened in
our clinical practice with standard vertebroplasty. Notably,
93% of patients previously carrying a brace were able to
stop its use after elastoplasty and 84% of patients were
able to completely stop the use of any pain relief drugs.
Thus, our results in terms of pain relief are similar to
those reported for standard vertebroplasty.
During the follow-up, no new vertebral fractures
occurred in our series. In the literature, several studies
reported on the development of new vertebral compression
fractures in patients treated with vertebroplasty [24–26]. In
a systematic review of the literature, Ma et al. [25] analysed
24 observational studies involving 3789 patients and found
strong evidence for three risk factors associated with new
vertebral fractures, including intradiscal cement leakage,
lower bone mineral density and lower body mass index.
On the other hand, the Vertos II study [27], a prospective
multicentre randomised controlled trial comparing verteb-
roplasty and conservative therapy, showed no difference in
the occurrence of new vertebral fractures between the two
groups, but new vertebral fractures were observed in 16.4%
of patients treated with vertebroplasty and in 24.7% of
patients who underwent conservative therapy. Among the
explanatory theories for new vertebral fractures correlated
with vertebroplasty, some authors hypothesised an induced
degenerative change in the adjacent bone due to an altered
load transfer caused by the fact that cement-filled bone is
much stiffer than cancellous bone [28–30]. In this scenario,
the application of a material softer than PMMA has been
suggested to reduce the stiffness of the treated vertebral
body and consequently the risk of adjacent vertebral new
fractures.
Some limitations of the present study need to be taken
into consideration. First, this is a retrospective analysis
on a limited number of patients treated over a long time
period for different pathologies by a single operator with
much experience in vertebral augmentation. These results
might therefore not apply to the everyday clinical practice
of any centre. Second, the presence of pulmonary embolism
was evaluated only based on patient symptoms. This was
due to the fact that we considered unjustified the radiation
exposure associated with a chest CT in asymptomatic
patients. Third, the occurrence of new vertebral fractures
during follow-up has been only evaluated at one month
with x-ray examinations and afterward only on the
basis of clinical symptoms reported by the patients.
Even if this might have determined an underestimation
of new vertebral fractures, it should be underlined that
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the aim of the treatment is to solve the patient’s symptoms
and that repeated radiological examinations in asymptom-
atic patients could be not justified.
In conclusion, elastoplasty with VK100 provided results
in terms of pain relief similar to those reported for the
most widely used vertebral augmentation techniques. The
rate of minor complications was low and similar to that
reported for other vertebral augmentation techniques.
Finally, the absence of new vertebral fractures at one
month after the procedure supports the rationale for
applying elastic material for vertebral augmentation.
However, even if the results from our preliminary
experience are encouraging, further large prospective
studies should be conducted to better define the role of
elastoplasty among vertebral augmentation techniques.
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